Kidney volume after endovascular exclusion of abdominal aortic aneurysms by EVAR and FEVAR.

Ann Vasc Surg

CHU Rennes, Service de Chirurgie Vasculaire, F-35033 Rennes, France; University of Rennes, Inserm, LTSI - UMR 1099, Rennes, France. Electronic address:

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Decreased kidney volume is a sign of renal aging and/or decreased vascularization. The aim of this study was to determine whether renal volume changes 24 months after exclusion of an abdominal aortic aneurysm (AAA), and to compare fenestrated (FEVAR) and subrenal (EVAR) stents.

Methods: Retrospective single-center study from a prospective registry, including patients between 60 and 80 years with normal preoperative renal function (eGFR≥60 ml/min/1.73 m) who underwent fenestrated (FEVAR) or infrarenal (EVAR) stent grafts between 2015 and 2021. Patients had to have had an CT scan at 24 months of the study to be included. Exclusion criteria were renal branches, the presence of preoperative renal insufficiency, a single kidney, embolization or coverage of an accessory renal artery, occlusion of a renal artery during follow-up and mention of AAA rupture. Renal volume was measured using sizing software (EndoSize, therenva) based on fully automatic deep-learning segmentation of several anatomical structures (arterial lumen, bone structure, thrombus, heart, etc.), including the kidneys. In the presence of renal cysts, these were manually excluded from the segmentation.

Results: Forty-eight patients were included (24 EVAR vs. 24 FEVAR), 96 kidneys were segmented. There was no difference between groups in age (78.9±6.7 years vs. 69.4±6.8, p=0.89), eGFR 85.8 ± 12.4 [62-107] ml/min/1.73 m vs. 81 ± 16.2 [42-107] (p=0.36), and renal volume 170.9 ± 29.7 [123-276] mL vs. 165.3 ± 37.4 [115-298] (p=0.12). At 24 months in the EVAR group, there was a non-significant reduction in eGFR 84.1 ± 17.2 [61-128] ml/min/1.73 m vs. 81 ± 16.2 [42-107] (p=0.36) or renal volume 170.9 ± 29.7 [123-276] mL vs. 165.3 ± 37.4 [115-298] (p=0.12). In the FEVAR group, at 24 months there was a non-significant fall in eGFR 84.1 ± 17.2 [61-128] ml/min/1.73 m vs. 73.8 ± 21.4 [40-110] (p=0.09), while renal volume decreased significantly 182 ± 37.8 [123-293] mL vs. 158.9 ± 40.2 [45-258] (p=0.007).

Conclusion: In this study, there appears to be a significant decrease in renal volume without a drop in eGFR 24 months after fenestrated stenting. This decrease may reflect changes in renal perfusion and could potentially be predictive of long-term renal impairment, although this cannot be confirmed within the limits of this small sample. Further studies with long-term follow-up are needed.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.avsg.2025.08.001DOI Listing

Publication Analysis

Top Keywords

renal volume
24
renal
15
kidney volume
8
exclusion abdominal
8
abdominal aortic
8
evar fevar
8
fenestrated fevar
8
preoperative renal
8
renal artery
8
ml/min/173 162
8

Similar Publications

A pediatric-onset case of chronic kidney disease caused by a novel sporadic variant and literature review.

Turk J Pediatr

September 2025

West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan, China.

Background: The α-actinin-4 (ACTN4) gene encodes an actin-binding protein, which plays a crucial role in maintaining the structure and function of podocytes. Previous studies have confirmed that ACTN4 mutations can lead to focal segmental glomerulosclerosis-1 (FSGS1), a rare disease primarily manifesting in adolescence or adulthood, characterized by mild to moderate proteinuria, with some cases progressing slowly to end-stage renal disease.

Case Presentation: We report a 12.

View Article and Find Full Text PDF

Copeptin in the diagnosis and management of renal tubular disorders.

Pediatr Nephrol

September 2025

Pediatric Nephrology Department, Biobizkaia Health Research Institute, Cruces University Hospital, Barakaldo, Spain.

Copeptin, a stable glycopeptide derived from the precursor of arginine vasopressin (AVP), has emerged as a valuable surrogate biomarker for AVP due to its stability and ease of measurement. This narrative review explores the physiological role of copeptin, its utility as a diagnostic and prognostic biomarker in different kidney diseases, and its clinical relevance in renal tubular disorders. The clinical application of copeptin as a diagnostic biomarker is best established in the differential diagnosis of polyuria-polydipsia syndrome (PPS), distinguishing nephrogenic diabetes insipidus (NDI) from central diabetes insipidus (CDI) and primary polydipsia (PP).

View Article and Find Full Text PDF

Regression equation for kidney function based on the ultrasonographic volumetry of the renal cortex.

J Nephrol

September 2025

Division of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Nishi-cho 36-1, Yonago, Tottori, 683-8504, Japan.

Background: Chronic kidney disease (CKD) is a public health concern; kidney size correlates with kidney function, except in diabetic kidney disease (DKD), where the kidney enlarges, limiting morphological measurement applications in CKD management. However, cortical size changes in DKD along with CKD progression remain understudied. We investigated kidney morphology alterations in patients with and without diabetes and established a regression equation for kidney function incorporating morphological alterations.

View Article and Find Full Text PDF

Unlabelled: -butyl cyanoacrylate is a liquid embolic material used to treat bleeding. Rebleeding may occur after -butyl cyanoacrylate embolization due to vasospasm and dilation of the embolized artery. However, the impact of vasospasm on -butyl cyanoacrylate embolization has not been fully investigated.

View Article and Find Full Text PDF

This case report describes a 56-year-old woman with autosomal dominant polycystic kidney disease and chronic renal failure who underwent transcatheter arterial embolization with N-butyl-2-cyanoacrylate-Lipiodol before renal transplantation. Both kidneys were significantly enlarged, necessitating transcatheter arterial embolization to reduce renal volume and create space for transplantation. The right kidney volume decreased from 2520 to 1150 mL within 9 months after transcatheter arterial embolization, enabling successful transplantation.

View Article and Find Full Text PDF